Table 2.

Non-haematological toxicity and second primary malignancy in relapsed/refractory multiple myeloma.

	Daratumumab-containing treatment (n/N, %)	Control treatment (n/N, %)
All grade peripheral neuropathy
CANDOR study	53/308 (17%)	13/153 (8%)
CASTOR study	115/243 (47%)	89/237 (37%)
Substudy of CASTOR study
Standard cytogenetic risk MM	67/137 (49%)	50/136 (37%)
High cytogenetic risk MM	22/40 (55%)	13/34 (38%)
Grade 3–4 peripheral neuropathy
CANDOR study	0/308 (0%)	0/153 (0%)
CASTOR study	11/243 (4.5%)	16/237 (6.8%)
Substudy of CASTOR study
Standard cytogenetic risk MM	4/137 (2.9%)	8/136 (5.9%)
High cytogenetic risk MM	2/40 (5.0%)	4/34 (12%)
All grade hypertension
Substudy of CASTOR study
Standard cytogenetic risk MM	15/137 (11%)	5/136 (3.7%)
High cytogenetic risk MM	4/40 (10%)	1/34 (2.9%)
Substudy of POLLUX study
Standard cytogenetic risk MM	12/192 (6.3%)	8/176 (4.5%)
High cytogenetic risk MM	9/35 (25.7%)	2/34 (5.9%)
Grade 3–4 hypertension
Substudy of CASTOR study
Standard cytogenetic risk MM	9/137 (6.6%)	1/136 (0.7%)
High cytogenetic risk MM	2/40 (5%)	0/34 (0%)
Substudy of POLLUX study
Standard cytogenetic risk MM	5/192 (2.6%)	2/176 (1.1%)
High cytogenetic risk MM	4/35 (11.4%)	0/34 (0%)
Acute cardiac failure
CANDOR study	23/308 (7.5%)	16/153 (10%)
Ischemic heart disease
CANDOR study	13/308 (4.2%)	5/153 (3.3%)
Acute renal failure
CANDOR study	18/308 (5.8%)	12/153 (7.8%)
Second primary malignancy
POLLUX study	8/286 (2.8%)	10/283 (3.6%)
CASTOR study	6/243 (2.5%)	1/237 (0.4%)